Russell Investments Group’s C4 Therapeutics CCCC Stock Holding History

Russell Investments Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.9K	Buy	+8,105	New	+$27.7K	﹤0.01%	3681
2023 Q4	–	Sell	-95,822	Closed	-$178K	–	3220
2023 Q3	$178K	Buy	95,822 +17,689	+23%	+$54K	﹤0.01%	2512
2023 Q2	$215K	Buy	78,133 +19,099	+32%	+$61.4K	﹤0.01%	2459
2023 Q1	$185K	Buy	59,034 +13,798	+31%	+$81.2K	﹤0.01%	2491
2022 Q4	$267K	Buy	45,236 +7,243	+19%	+$60.1K	﹤0.01%	2494
2022 Q3	$332K	Sell	37,993 -648	-2%	-$6.73K	﹤0.01%	2393
2022 Q2	$290K	Buy	+38,641	New	+$340K	﹤0.01%	2448
2021 Q4	–	Sell	-5,056	Closed	-$225K	–	3002
2021 Q3	$225K	Buy	5,056 +4,494	+800%	+$192K	﹤0.01%	2742
2021 Q2	$21K	Buy	+562	New	+$20.1K	﹤0.01%	3175

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Russell Investments Group's CCCC Position: Q2 2026 in Review

Russell Investments Group opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 8,105 shares worth $37.9K. The stake represents ﹤0.01% of the portfolio and ranks #3681 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in CCCC as recently as Q3 2023.

Russell Investments Group first reported a position in CCCC in Q2 2021 and has held it in 9 quarters since. The position peaked at $332K in Q3 2022. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Russell Investments Group held 8,105 shares of C4 Therapeutics worth $37.9K as of Q2 2026.
C4 Therapeutics was a new Russell Investments Group position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3681 holding.
Russell Investments Group first reported a position in C4 Therapeutics in Q2 2021 and has held it in 9 quarters since.
Russell Investments Group's C4 Therapeutics position peaked at $332K in Q3 2022.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.